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Small cell carcinoma of the prostate is a rare neoplasm, with only a few series hitherto reported. A little less than half of the
cases are associated with conventional acinar adenocarcinoma, which are usually high grade. Although consensus has not been
reached, the majority of patients with small cell neuroendocrine carcinoma of the prostate have advanced disease at diagnosis and
disproportionally low PSA levels compared to patients with conventional acinar adenocarcinoma. Treatment consists mainly of
chemotherapy associated with surgery. Radiation therapy is reserved for selected cases. This study reviews the most up-to-date
information on small cell carcinomas of the prostate.
1.Introduction
Small cell neuroendocrine carcinoma of the prostate is a
very uncommon type of prostate cancer, which was ﬁrst
described by Wenk et al. [1]. Lacking a speciﬁc classiﬁcation,
neuroendocrine tumors of the prostate are usually reported
as carcinoid tumors, which are low-grade neuroendocrine
carcinomas, and high-grade neuroendocrine carcinoma,
which encompasses large neuroendocrine, small cell neu-
roendocrine carcinoma, and combined tumors, based on
their histological and immunophenotypical proﬁle [2–7].
Barely more than half of small cell carcinomas arising
in the prostate are pure without an associated nonsmall cell
component.Alargenumberofcasesaredetectedafterandro-
gen ablation therapy for conventional adenocarcinoma. In
these situations, conventional acinar adenocarcinoma cells
may diﬀerentiate along neuroendocrine lines [8].
Theimportanceinrecognizingsmallcellneuroendocrine
carcinoma resides in its histological overlap with primary
high Gleason-grade tumors of the prostate and its biological
behavior, which implies in a diﬀerent clinical presentation
and treatment approach [9, 10].
Herein, we review the most up-to-date information
on small cell neuroendocrine carcinoma of the prostate,
focusing on its histological, immunophenotypical proﬁle
as well the most important diﬀerential diagnosis. Brief
considerations on molecular pathology advances as well as
treatment options are also stated.
2. Methods
A literature search for small cell neuroendocrine carcinoma
of the prostate was performed. Referred articles were selected
and reviewed, and data concerning clinical data of cancer
occurrence, histological settings, immunohistochemical and
molecular proﬁles, and treatment options are here discussed.
3. Discussion
Smallcellneuroendocrinecarcinomaisrareoutsidethelung.
Approximately 10% cases occur in the prostate, making it
one of the most common extrapulmonary sites [3, 6, 8,
9, 11–17]. PSA serum levels can vary from undetectable,
especially in cases of conventional acinar tumors with prior
hormone treatment, to high levels, with a mean level of
4.0ng/dL(range 0–1896) in one large series [2, 6, 18, 19]. In
this series, the interval between the diagnosis of small cell
carcinoma subsequent to one of conventional tumors had
a mean of 25 months [6]. Interestingly, in another series2 Prostate Cancer
Figure 1: Low power of small cell carcinoma (left) associated with
Gleason 7 acinar adenocarcinoma (right).
focusing on large cell neuroendocrine carcinoma (LCNEC),
the interval between initial diagnosis of conventional tumor
washigher,withameanof4.7years[2].Stageatpresentation
seems also to be higher in cases of tumors with neuroen-
docrine diﬀerentiation that were not subject to hormonal
treatment [20].
In clinical studies where serum levels of PSA and
chromogranin are followed, patients with increasing levels
of those markers are diagnosed in an interval of 10 to 30
months, although it is still controversial if serum chromo-
granin levels independently correlate with prognosis and/or
the presence of neuroendocrine diﬀerentiation in a given
tumor [21–24].
Histologicalﬁndingsareidenticaltothosetumorsarising
in extraprostatic sites: in small cell carcinoma, neoplastic
cells are arranged mostly in a monomorphic pattern of small
round or fusiform cells containing oval or convoluted hyper-
chromatic nuclei with a salt-and-pepper pattern chromatin,
rarely with one or more discernible small nucleoli (Figure 1).
Two types of tumor cells can be seen, the classic “oat cell”
morphologyandalsoanintermediatecell-typevariantwhich
have been described previously in other sites of the body
[6]. The classic morphology is characterized by cells only
slightly larger than lymphocytes with open chromatin and
inconspicuous nucleoli, wherein the intermediate cell type,
thetumorcellshavemoreabundantcytoplasm,largernuclei,
and occasional visible nucleoli [6].
Pure small cell neuroendocrine carcinomas of the
prostate are slightly more common than mixed small cell-
adenocarcinomas. The latter occur usually with a high-grade
component (Gleason≥8) (Figures 2 and 3)[ 2, 6, 25, 26].
Cytoplasmisscant.Mitosesarereadilydiscernibleandcanbe
numerous. Necrosis is another common histological ﬁnding
but is usually not extensive. Perineural invasion is also
common (Figure 4). Larger atypical cells, formation of true
rosettes or pseudorosettes, and a large clear and vacuolated
cytoplasm are also described. Another spectrum of neuroen-
docrine diﬀerentiation encompasses Paneth cell-like change.
This phenomenon was reported by Weaver et al. and is
characterized by the presence of small eosinophilic cytoplas-
matic granules resembling intestinal Paneth cells in prostate
cancer. Its true neuroendocrine origin is conﬁrmed by
immunohistochemicalandelectronmicroscopystudies[27].
For the surgical pathologist, the most critical and com-
mon issue concerning the diagnosis of a small cell neuroen-
docrine carcinoma is its confusion with a poorly diﬀerenti-
Figure 2: Combined acinar adenocarcinoma and small cell carci-
noma diagnosed in a needle biopsy.
Figure 3 :T h es a m ec a s ea si nFigure 2. Note gradual merging of
small cell carcinoma with glands of acinar adenocarcinoma.
ated acinar adenocarcinoma (Gleason 5), notably those with
a solid pattern without gland formation and central necrosis
in a small focus on needle biopsies. Indeed, misdiagnosing
small cell carcinomas as high-grade acinar adenocarcinoma
seems to occur commonly. Studies reveal a 0.5–2% incidence
of small cell carcinoma in patients diagnosed in biopsies as
opposed to a 10%–20% ﬁgure in autopsies cases [28, 29].
Although not required for the diagnosis of small cell
carcinoma, immunohistochemical studies may be helpful
(Table 1). A comprehensive immunohistochemical panel to
diﬀerentiate small cell carcinoma from poorly diﬀerentiated
adenocarcinoma includes PSA, PSAP, P501s, and neuroen-
docrine markers, CD 56 being the most sensitive for small
cell carcinoma (Figures 5 and 6). TTF-1 can be positive in up
tohalfofsmallcellcarcinomasandisnotfoundinthepoorly
diﬀerentiatedadenocarcinomas[6,17].Mostsmallcellcarci-
nomas are negative for the aforementioned prostate markers
(PSA, PSAP, and P501S), with some rare cases showing focal
positivity, while poorly diﬀerentiated adenocarcinomas are
usually diﬀusely positive for the same antibodies. Expression
of neuroendocrine markers can be seen in conventional aci-
nar adenocarcinomas, and the diagnosis of neuroendocrine
carcinomas should rely in both immunohistochemical pro-
ﬁle and light microscopic morphology.
Pulmonary small cell carcinomas are aggressive neo-
plasms commonly in advanced stages at diagnosis. PSAProstate Cancer 3
Table 1: Immunohistochemical ﬁndings of small cell carcinoma of
theprostatecomparedwithconventionalhigh-gradeadenocarcino-
mas [6, 8, 10, 17, 20, 30–35].
Antibody
Small cell carcinoma Poorly diﬀerentiated
(approximate adenocarcinoma
percentage of (approximate percentage
positivity) of positivity)
Cytokeratin (94%) + (70%)
Cytokeratin high (35%) −/+ − (0-33%)
molecular weight
CAM 5.2 (72%) + (90%)
CK 7 (39%) −/+ −/+ (30%)
CK 20 (11%) −/+ −/+ (10%)
PSA (24%) −/+ ++ (85%)
PSMA (20%) −/+ ++ (90%)
PSAP (22%) −/+ ++ (95%)
P501s (25%) −/+ ++ (90%)
p63 (40%) −/+ –/+ (15%)
TTF1 (83%) +/−− (10%)
CD 56 (92%) + − (10%)
Chromogranin (80%) + − (10%)
Synaptophysin (85%) + −/+ (13%)
CD44 (60-96%) ++ − (5%)
Figure 4: Perineural invasion by the small cell carcinoma compo-
nent, diagnosed in a needle biopsy.
serum levels are not commonly elevated in primary small
cell carcinomas of the prostate, and its levels are not helpful
in separate metastatic lung disease from prostate small
cell carcinoma. Immunohistochemistry can be helpful in
distinguishing them, as small cell carcinomas can be positive
(even focally) for at least one prostatic marker (PSA, PSMA,
PSAP, or P501s) which are not expressed in lung tumors
[36]. CD44, a cell-surface molecule proposed to identify
cancer stem/progenitor cells in prostate cancer, has been
demonstrated to be highly speciﬁc of small cell carcinoma
of the prostate, when compared to conventional acinar ade-
nocarcinoma or small cell carcinomas of other sites [10, 30].
The recent discoveries of the TMPRSS2-ERG rearrange-
ment in subset of prostate cancer, with prevalence between
Figure 5: PSA immunostain showing strong positivity in benign
prostate glands, whereas the neuroendocrine tumor is faint to
absent.
Figure 6: Small cell carcinoma with strong positivity for chromo-
granin immunostain.
40–70% of all tumors, raised the question of the presence of
this genetic aberration in more aggressive forms of prostate
tumors. Two recent papers have addressed the issue of the
translocation in small cell carcinomas of the prostate. Guo et
al. [37] evaluated the TMPRSS2-ERG gene fusion in 12 small
cell carcinomas of the prostate with small cell carcinomas
of the bladder and lung as control, by ﬂuorescent in situ
hybridization (FISH), and found the aberration in about
67% of the cases and in none of the controls. In a similar
study, Lotan et al. [38] also found the ERG translocations
in more than 45% of small cell carcinoma of the prostate,
and in cases where the acinar component was also available
for analysis, there was concordance for the presence/absence
of ERG gene rearrangement between the diﬀerent subtypes.
These ﬁndings strongly suggest a common pathway of
genesis of conventional acinar and also small cell carcinoma
of the prostate.
More recent data on molecular characterization of small
cell carcinoma of the prostate reported by Tai et al. [39]h a v e
shown speciﬁc association of those cases with PC3, one cell4 Prostate Cancer
line related to prostatic carcinoma. Indeed, those cells are
immunohistochemically characterized by the expression of
CD44, a stem cell marker commonly reported and believed
to be more speciﬁc for small cell carcinoma of the prostate.
On the contrary, conventional adenocarcinoma do not show
CD44 positivity and have expression of PSA and androgen
receptorslikeLNCaP,anotherknowncelllineassociatedwith
prostatic carcinoma [39].
The treatment of small cell carcinoma of the prostate
includes a multimodality approach with chemotherapy as
the mainstay of treatment, and radiation as supplemental
for local control or for palliation. However, no uniform
treatment being clearly established. Regimens that include
gemcitabine, docetaxel and carboplatin, or cisplatin have
been attempted with variable success [40–42]. Radiotherapy
is also used, since patients with a small carcinoma diagnosis
are not common candidates for surgical treatment [10, 14,
43, 44]. However, primary surgery was the most important
prognostic factor for prolonged survival in one study [45].
Neuroendocrine diﬀerentiation may play an important role
in the development of androgen resistance [14, 41], and
advanced prostatic carcinomas with pure or partial neu-
roendocrine diﬀerentiation have a median survival of only
10 months. However, a case of mixed conventional acinar
adenocarcinoma and small cell neuroendocrine carcinoma
recentlyreportedbyBrammeretal.treatedwithconcomitant
hormonal and chemotherapy showed complete remission of
disease 36 months after the initial diagnosis [46].
Another potential target for the treatment of small cell
neuroendocrine carcinoma is the relaxin receptor RXFP1.
Relaxin is a small peptide hormone expressed in several can-
cers such as those of endocrine origin. Its receptor, RXFP1 (a
G-protein-coupledreceptor),isexpressedinandrogenrecep-
tors’positive andnegativecancers,aswellasinprostategerm
cells. In PC3 prostate cancer cell lines, which include small
cell neuroendocrine carcinoma, treatment of RXFP1 showed
signiﬁcant reduction of tumor size, decrease in cell prolifer-
ation and metastatic disease, and increased apoptosis [47].
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